Combined rituximab and belimumab to treat recalcitrant epidermolysis bullosa aquisita associated with systemic lupus erythematosus-Reference-Cited by-同舟云学术

Combined rituximab and belimumab to treat recalcitrant epidermolysis bullosa aquisita associated with systemic lupus erythematosus

Published:2024-04-02 Issue:1 Volume:191 Page:138-140
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Tull Thomas J¹^ORCID,Benton Emma C¹,Semkova Kristina¹,Watson Natalie A²,Mee John B¹,Lopez Begona³,Setterfield Jane¹,Carey Barbara¹,Ahmad Sajjad⁴,Robbie Scott J⁵,Groves Richard W¹,Sanna Giovanni³,D’Cruz David P³

Affiliation:

1. St John’s Institute of Dermatology

2. Ear, Nose and Throat Department

3. Louise Coote Lupus Unit

4. Moorfields Eye Hospital NHS Foundation Trust , London , UK

5. Department of Ophthalmology, Guy’s and St Thomas’ NHS Foundation Trust

Abstract

We report two cases of recalcitrant epidermolysis bullosa aquisita with associated systemic lupus erythematosus treated with combination rituximab and belimumab therapy. This resulted in the complete resolution of cutaneous lesions and a partial response of the mucosal lesions. These cases support the use of combined rituximab and belimumab for the treatment of recalcitrant immunobullous disease.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae141/57400557/ljae141.pdf

Reference7 articles.

1. Epidermolysis bullosa acquisita: a comprehensive review;Kridin;Autoimmun Rev,2019

2. Autoimmune bullous dermatoses;Holtsche;J Dtsch Dermatol Ges,2023

3. Case report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review;Szymanski;Front Immunol,2023

4. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial;Shipa;Ann Intern Med,2021

5. B cell biomarkers of rituximab responses in systemic lupus erythematosus;Vital;Arthritis Rheum,2011